Bicara Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Bicara Therapeutics Inc 's ROA in the second quarter of 2026?
Bicara Therapeutics Inc recorded a cumulative net loss of $-185 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -38.59%.

However, within the Healthcare sector 473 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3702, from total ROA ranking in the first quarter of 2026 at 4294.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	13.45 %	15.8 %	-15.44 %	-18.98 %	67.76 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-185	-157	-138	-122	-103
Return On Assets (TTM)	-38.59 %	-33.82 %	-30.91 %	-26.08 %	-20.92 %
BCAX's Total Ranking	# 3702	# 4294	# 3682	# 3603	# 3651
Total Assets (TTM) in million	512	554	431	425	452
Seq. Total Assets Change	-7.47 %	28.45 %	1.48 %	-5.94 %	-5.56 %
Seq. Net Income Change	-	-	-	-	-

BCAX's 5 Years Annual ROA >> Back to BCAX Management Effectiveness >> Compare BCAX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 188
Sector	# 474
Overall	# 3739

Return On Assets Statistics
High	Average	Low
-20.89 %	-28.55 %	-38.59 %
(Jun 30 2025)		(Jun 30 2026)

Financial Statements
Bicara Therapeutics Inc 's Assets	$ 512 million	BCAX's Balance sheet
Bicara Therapeutics Inc 's Income	$ -55 million	Quarterly BCAX's Income Statement
BCAX's Income by Division		See BCAX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	FY	FY	FY
Y / Y Total Assets Change	-15.44 %	-	-	-	-
Total Assets in million	431	510	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-138	-68	0	0	0
Annual Return On Assets	-32.01 %	-13.34 %	-	-	-

BCAX's 5 Years Annual ROA >> Back to BCAX Management Effectiveness >> Compare BCAX ROA to its Competitors

More Return On Assets Ratios
BCAX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BCAX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BCAX's Competitors
Subscribers only: Roa for Bicara Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for BCAX's Customers

You may also want to know
BCAX's Roi	BCAX's Inventory Turnover Ratio	BCAX's Growth Rates	BCAX's Dividend Comparisons
	BCAX's Profitability Ratios	BCAX's Asset Turnover Ratio	BCAX's Dividend Growth
BCAX's Roe	BCAX's Valuation Ratios	BCAX's Financial Strength Ratios	BCAX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:43:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.